Stock BIIB BIOGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Biogen Inc.

Equities

BIIB

US09062X1037

Real-time Estimate Cboe BZX
Other stock markets
 02:52:23 2024-04-26 pm EDT 		5-day change 1st Jan Change
209.8 USD +3.64% Intraday chart for Biogen Inc. +7.68% -19.11%
05:33pm Guggenheim Adjusts Price Target on Biogen to $255 From $275 MT
Apr. 25 Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA CI

Evolution of the average Target Price on Biogen Inc.

Price target over the last 5 years

History of analyst recommendation changes

171e97a.pkday-E2viszwiyli9RVnXrxmTCwupEYArhWSzSuNgc.4Q5oo4lYjGxVgBvJ5qBk3CXA8nWI3sV_UNYlKAX3RGT8Bi6gjlPhH3-LbQ~29a1217ee4f88cb9057f8f7f767d6fd1

Analyst Recommendations on Biogen Inc.

Guggenheim Adjusts Price Target on Biogen to $255 From $275 MT
Goldman Sachs Adjusts Biogen Price Target to $340 From $393 MT
Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305 MT
Barclays Adjusts Price Target on Biogen to $200 From $215 MT
HC Wainwright Adjusts Biogen's Price Target to $300 From $325 MT
Wedbush Adjusts Price Target on Biogen to $215 From $213 MT
Morgan Stanley Cuts Biogen's Price Target to $331 From $339 MT
Piper Sandler Raises Biogen's Price Target to $335 From $325 MT
RBC Lowers Biogen's Price Target to $317 From $326 MT
Needham Adjusts Price Target on Biogen to $294 From $300 MT
BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept MT
Oppenheimer Adjusts Biogen Price Target to $270 From $290 MT
UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating MT
Wedbush Cuts Biogen's Price Target to $213 From $245 MT
Argus Adjusts Biogen's Price Target to $240 From $315 MT
Goldman Sachs Cuts Biogen's Price Target to $393 From $400 MT
JPMorgan Cuts Biogen's Price Target to $240 From $270, Maintains Neutral Rating MT
Morgan Stanley Trims Price Target on Biogen to $339 From $346, Keeps Overweight Rating MT
Barclays Cuts Price Target on Biogen to $215 From $230, Maintains Equalweight Rating MT
BIOGEN : Jefferies confirms its Buy rating on the stock CF
Canaccord Genuity Adjusts Price Target on Biogen to $305 From $310, Keeps Buy Rating MT
UBS Cuts Biogen Price Target to $250 From $276, Maintains Neutral Rating MT
Oppenheimer Adjusts Biogen Price Target to $290 From $295, Maintains Outperform Rating MT
The market faces a choice Our Logo
Baird Adjusts Biogen Price Target to $316 From $333, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
202.5 USD
Average target price
286.5 USD
Spread / Average Target
+41.53%
High Price Target
350 USD
Spread / Highest target
+72.87%
Low Price Target
200 USD
Spread / Lowest Target
-1.22%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Biogen Inc.

Goldman Sachs
Canaccord Genuity
Barclays
HC Wainwright
Wedbush
Morgan Stanley
Piper Sandler
RBC Capital Markets
Needham & Co.
BMO Capital
Oppenheimer
UBS
Argus
JPMorgan Chase
Baird
TD Cowen
Stifel Nicolaus
Scotiabank
Wells Fargo Securities
BofA Securities
Raymond James
HSBC
Mizuho Securities
Atlantic Equities
Guggenheim
Jefferies & Co.
Truist Securities
Cowen
SVB Securities LLC
SVB Leerink
Cantor Fitzgerald
Bernstein
William Blair & Co.
Citigroup
Credit Suisse
DZ Bank

Ratings for Biogen Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. Consensus Biogen Inc.